APPLICATION
ANDA207736
TYPE
ANDA
ORIGINAL APPROVAL
2023-02-10
LATEST ACTION
2024-04-04
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued
Products
CABAZITAXELDiscontinued
CABAZITAXEL 60MG/1.5ML (40MG/ML) · SOLUTION · INTRAVENOUS
Approval history
2024-04-04Labeling · Supplement 2 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.